Billions of dollars of debt incoming as Allergan shareholders agree takeover

pills
By Mike Turner
17 Oct 2019

Allergan shareholders have waved through its acquisition by rival drug company AbbVie, clearing a major hurdle on the way to billions of dollars of loans and an expected $30bn of bond issuance.

Votes representing around 68.6% of outstanding shares in US pharmaceuticals company Allergan were cast at an extraordinary general meeting this week, with the overwhelming majority of those — more than 99% — in favour of the acquisition. 

“This combination will create a leading biopharmaceutical company with a diversified portfolio ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.